LEO Pharma Connects Affiliates with Veeva Vault Safety
Veeva Systems has announced that LEO Pharma is using Veeva Vault Safety to optimize its safety operations. With this foundation, the company can incorporate affiliates into safety workflows, boost operational efficiencies, ensure compliance, and unify its global pharmacovigilance data on one platform.
“LEO Pharma is deeply committed to the safety of patients using its products,” said Pilar Carrero, vice president of global safety at LEO Pharma in a press release. “With Veeva Vault Safety, we now have real-time visibility into adverse events and data transparency for affiliates that helps us work even better together.”
Vault Safety is helping LEO Pharma improve oversight of case intake, processing, submission, and distribution while simplifying safety workflows and eliminating data reconciliation with affiliates and partners. By standardizing drug development on Veeva Development Cloud, LEO Pharma can better connect safety to other crucial business areas like clinical, regulatory, and quality.
“Now, all parties have visibility into case data, ownership, and status, facilitating improved collaboration and sharing of learnings,” said John Lawrie, vice president of Vault Safety at Veeva in a press release. “Veeva is happy to partner with LEO Pharma to make its safety operations simpler and more effective.”
Vault Safety is a safety case management system that enables adverse event intake, processing, and submission for clinical and marketed products. It is part of Veeva Development Cloud.
Reference
LEO Pharma Connects Affiliates with Veeva Vault Safety to Transform Safety Operations. (2023, October 3). Veeva.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
